This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Recurrent miscarriage: diabetes drug could ... An existing drug can be used to improve the womb for pregnancy, ... (08 Jan 2020)
Nerve Stimulation May Benefit Women with ... A treatment involving electrical nerve stimulation helped women ... (08 Jan 2020)
Cancer drugs could potentially treat COPD, ... New research from the University of Sheffield shows a certain ... (08 Jan 2020)
Tea drinkers live longer Drinking tea at least three times a week is linked with a longer ... (08 Jan 2020)

Early Use of Antibiotic for Recurrent, Severe Lower Respiratory Illness in Children

child coughAmong young children with histories of recurrent severe lower respiratory tract illness (LRTI), the use of azithromycin early during an apparent RTI compared with placebo significantly reduced the risk of experiencing progression to severe LRTI, according to a study in the November 17 issue of JAMA.
Acute episodes of severe LRTI are common among preschoolers, and up to 14 percent to 26 percent of preschoolers present with recurrent wheezing during the first 6 years of life. These severe episodes are often associated with substantial illness, and may result in visits to urgent care and emergency departments. Although viral infections are often present, bacteria may also contribute to illness development. Identification of treatment approaches that lessen the severity of these recurrent episodes would provide substantial benefit to preschool children with recurrent severe LRTI, according to background information in the article.
Leonard B. Bacharier, M.D., of the Washington University in St. Louis School of Medicine, and colleagues randomly assigned 607 children (age 12 months through 71 months) with histories of recurrent, severe LRTIs to receive the antibiotic azithromycin (for 5 days; n = 307) or matching placebo (n = 300), started early during each predefined RTI (child's signs or symptoms prior to development of LRTI), based on individualized action plans. The trial was conducted across 9 academic U.S. medical centers in the National Heart, Lung, and Blood Institute's AsthmaNet network.
A total of 937 treated RTIs (azithromycin group, 473; placebo group, 464) were experienced by 443 children (azithromycin group, 223; placebo group, 220), including 92 severe LRTIs (azithromycin group, 35; placebo group, 57). The azithromycin group experienced a significantly lower risk of progressing to severe LRTI than the placebo group. Adverse events were infrequently observed.
Although limited to 86 participants at a single study site, the researchers found numerically higher rates of acquisition of azithromycin-resistant organisms in oropharyngeal samples in participants receiving azithromycin and those who did not, along with evidence of acquisition of azithromycin-resistant organisms even in participants not treated with azithromycin. “Real-world rates of development of azithromycin-resistant organisms may be greater, potentially due to failure to complete the full duration of therapy often seen in clinical practice. Given the small sample size, further studies are needed to assess the potential increased risk of antibiotic resistance vs the comparative effectiveness of azithromycin with respect to other asthma medications to prevent severe LRTI,” the authors write.
“In children with the phenotype of wheezing studied herein, clinicians may consider a therapeutic trial of azithromycin early in the course of RTIs based on a parent-initiated individualized plan. Children who demonstrate an azithromycin response, as reflected by less-severe episodes of RTI, may benefit from repeating such therapy with subsequent illnesses.”
“Studies replicating the findings reported herein would provide further support to this conclusion, and future studies comparing the relative benefits of early azithromycin therapy with either daily or intermittent high-dose inhaled corticosteroids may help determine the relative efficacies of these treatment strategies.”


Source Newsroom: JAMA - Journal of the American Medical Association
Citations
JAMA

Highlights

  • Nescafé 3 in1 LifeCycle HEROES return from South Asia

    Donations for Nescafé 3in1 LifeCycle Challenge 2019 can be sent via sms: 5061 7370 = €2.33; 5061 8920 = €6.99; 5061 9229 = €11.65; or via a call to 5160 2020 = €10, 5170 2005 = €15; and 5180 2006 = €25. Bank details are Swift code VALLMTMT, IBAN number MT 18 VALL 22013000000014814521017, Bank name Bank of Valletta, Account number 14814521017.

    Read more...
  • Give a Gift this Christmas which gives back

    The story of medicine is the story of civilization, from an ancient craft of primitive magic and religion to the sophisticated field of science and technology of today.

    Read more...

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…